English
Home > Products > CAS NO 147118-37-4

China CAS NO 147118-37-4 Factory

Dependable high-quality and fantastic credit standing are our principles, which will help us at a top-ranking position. Adhering to your tenet of "quality very first, client supreme" for CAS NO 147118-37-4,147118-37-4,Rosuvastatin intermediate,Rosuvastatin advance intermediate,4-(4-Fluorophenyl)-6-isopropyl, We welcome new and previous consumers from all walks of lifestyle to speak to us for upcoming business enterprise associations and mutual results!
CAS NO 147118-37-4, We integrate all our advantages to continuously innovate, improve and optimize our industrial structure and product performance. We are going to always believe in and work on it. Welcome to join us to promote green light, together we'll make a better Future!

Related Products

Hot Products

  • Tenofovir

    Tenofovir

    Product Name:Tenofovir
    Molecular Formula:C9H14N5O4P
    Molecular Weight:287.21
    CAS Registry Number:147127-20-6
  • Lanreotide Acetate

    Lanreotide Acetate

    Product Name:Lanreotide Acetate
    Molecular Formula:C54H69N11O10S2
    Molecular Weight;1096.326
    CAS Registry Number;127984-74-1
  • 4-Fluorobenzaldehyde

    4-Fluorobenzaldehyde

    Product Name:4-Fluorobenzaldehyde
    Molecular Formula:C7H5FO
    Molecular Weight:124.11
    CAS Registry Number:459-57-4
  • n-Butyllithium

    n-Butyllithium

    Product Name:n-Butyllithium
    Molecular Formula:C4H9Li
    Molecular Weight:64.06
    CAS Registry Number:109-72-8
  • 1,4-Butane-disulfonate

    1,4-Butane-disulfonate

    Product Name:1,4-Butane-disulfonate
    Molecular Formula:C4H10O6S2
    Molecular Weight:218.25
    CAS Registry Number:27665-39-0
  • Camostat mesilate

    Camostat mesilate

    Product Name:Camostat mesilate
    Molecular Formula:C21H26N4O8S
    Molecular Weight;494.52
    CAS Registry Number;59721-29-8
  • Related Blog
  • Reviews

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept